LifeVantage Corporation (LFVN) AI Stock Analysis

Headquartered in Lehi, Utah, LifeVantage Corporation researches, develops, formulates, and distributes nutrigenomic activators, dietary supplements, and personal care products. Its product offerings include nutraceuticals under the Protandim brand, LifeVantage Omega+, ProBio digestive supplements, and PhysIQ weight management solutions. It also produces IC Bright for eye and brain health, Petandim for Dogs, and TrueScience anti-aging skincare and hair care products. The company distributes its portfolio via its website and independent distributors across international markets including the United States, Mexico, Japan, and Australia.

LifeVantage's revenue fluctuated over recent fiscal years, moving from $206.4M in FY2022 to $213.4M in FY2023, then $200.2M in FY2024, before rising 14.2% to $228.5M in FY2025. In FY2026, revenue fell 20.1% to $182.6M, reflecting a 5-year revenue CAGR of -3.7%. Gross margin contracted to 77.6% in FY2026 compared to 80.4% in FY2025, while operating margin declined from 5.3% to 3.3%. Net income dropped from $9.8M in FY2025 to $5.1M in FY2026, with EPS declining to $0.56. For the latest quarter ended June 30, 2026, quarterly revenue fell 23.1% year-over-year and quarterly earnings decreased 32.8%.

As of June 30, 2026, LifeVantage held $14.9M in cash and short-term investments against total debt of $9.9M, resulting in net cash of $5.1M. Total assets stood at $62.1M and shareholders' equity was $33.6M, supported by a current ratio of 1.89 and a debt-to-equity ratio of 0.29. In FY2026, the company generated $10.2M in operating cash flow and $6.7M in free cash flow. Capital expenditures totaled $3.6M, while capital returns included $2.0M in share buybacks and $2.3M in dividends paid.

LifeVantage trades at an enterprise value of $71.9M and a market capitalization of $75.5M. The stock has a trailing P/E of 15.0x and an EV/EBITDA of 8.1x, both below the median of its US-listed Consumer Defensive peers at 18.6x and 11.7x, respectively. However, its forward P/E of 37.5x sits above the peer median of 14.3x. LifeVantage shares closed at $6.00 on October 16, 2026, falling 31.0% over the past year compared to a 16.8% gain for the S&P 500. Over five years, the stock gained 3.4% against 83.0% for the S&P 500.

LifeVantage pays an annual forward dividend of $0.20 per share, representing a dividend yield of 3.33% on a quarterly payment frequency. The dividend payout ratio stands at 33.9%, and the company has paid dividends for 5 consecutive years. Its most recent ex-dividend date occurred on September 1, 2026.

Wall Street analysts covering LifeVantage maintain 1 Strong Buy and 1 Hold rating. The mean price target is $7.50, representing a 25.0% premium over the last close of $6.00. For the current fiscal year ending June 30, 2027, consensus estimates project revenue of $165.5M and EPS of $0.32, representing an EPS decline of 42.3%. The company had 0 EPS beats over the last 4 quarters, and its next earnings date is November 3, 2026.

This page is an AI-written research summary of LifeVantage Corporation (LFVN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LFVN income statement, LFVN balance sheet, LFVN key metrics, LFVN analyst forecast, LFVN chart. See the LFVN stock overview for the latest quote and news.